TOMedica Solutions launches new Web site
GERMANTOWN, Wis. TOMedica Solutions has launched a new Web site, www.tomedica.com, to help emerging biopharma and/or pharmaceutical companies looking for retail, trade and distribution support when entering the U.S. market.
The site will show the company’s expertise in such areas as trade account management/operations consulting and retail marketing. A menu will be available for users to view cases studies on topics including “How to Improve Market Penetration” and “Creating Value through Distribution Management.”
Glenn Esgro, a managing partner with TOMedica Solutions commented, “As with any new company launch, the more information we can share about our services and experience, the better potential clients will know how we can best serve their needs. The TOMedica website will help to become the main portal for the introduction of TOMedica Solutions to Pharma companies overall.”
Takeda could see Alogliptin approval in near future
OSAKA, Japan Japanese pharmaceutical manufacturer Takeda’s new diabetes drug could get approval soon, according to Bloomberg.
According to the financial news agency, reports by analysts showed that the drug, alogliptin, had promise after the American Diabetes Association released parts of nine studies of the medication that were submitted for marketing approval in the U.S. in January, last week. They show the drug lowered blood sugar levels as much as Merck’s Januvia without serious side effects.
Alogliptin, also known as SYR-322, will compete with Merck’s Januvia and Novartis’ Galvus, which is also up for approval at the Food and Drug Administration. All three drugs are in a new class of diabetes treatments known as DPP4 inhibitors that signal the pancreas to produce more insulin and the liver to make less glucose, or blood sugar.
Assuming approval by the Food and Drug Administration, Alogliptin will succeed Actos, which generates about 29 percent of Takeda’s current revenue. Actos will lose patient approval in 2011.
Accutane ingredient linked to increased risk of depression
NEW YORK A study published in the Journal of Clinical Psychiatry has shown a link between use of the acne drug isotretinoin and increased risks of depression.
The drug was shown to more than double the risk of depression in a study of more than 30,000 people in Quebec who had received at least one prescription for it between 1984 and 2003.
Roche Pharmaceuticals’ drug Accutane has isotretinoin as its main active ingredient. The FDA originally granted approval to the drug in 1982.